MODELING THE COST-EFFECTIVENESS OF THE ALL ORAL, DIRECT-ACTING ANTIVIRAL REGIMEN DACLATASVIR PLUS SOFOSBUVIR IN PATIENTS CO-INFECTED WITH HEPATITIS C VIRUS (HCV) AND HIV

被引：3

作者：

McEwan, P. ^{[1
]}

Ward, T. ^{[1
]}

Webster, S. ^{[1
]}

Kalsekar, A. ^{[2
]}

Brenner, M. ^{[3
]}

Yuan, Y. ^{[2
]}

机构：

[1] Hlth Econ & Outcomes Res Ltd, Monmouth, Wales

[2] Bristol Myers Squibb Pharmaceut Ltd, Princeton, NJ USA

[3] Bristol Myers Squibb Pharmaceut Ltd, Uxbridge, Middx, England

来源：

VALUE IN HEALTH | 2015年 / 18卷 / 07期

关键词：

D O I：

10.1016/j.jval.2015.09.2213

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PGI32

引用

页码：A628 / A628

页数：1

共 50 条

[21] Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C
Pingyu Chen
Min Jin
Yang Cao
Hongchao Li
Applied Health Economics and Health Policy, 2021, 19 : 371 - 387
[22] Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings
Chen, Cheng-Pin
Cheng, Chien-Yu
Zou, Huachun
Cheng, Chun-Han
Cheng, Shu-Hsing
Chen, Cheng-Kuo
Chen, Ching-Hsiang
Bair, Ming-Jong
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2019, 52 (04) : 556 - 562
[23] Characteristics and effectiveness in HCV mono-infected and HIV - HCV co-infected cirrhotic patients receiving oral direct-acting antiviral (DAA) regimens interferon-free therapies in southern Spain
Alcaraz, Begona
Vera, Francisco
Escribano, Paloma
Rojano, Rocio
Jimeno, Amaya
Ruiz, Elena
Garcia, Ana
Trujillo, Javier
Cobos, Nazaret
Bernal, Enrique
Alcalde, Mar
Garcia, Josefina
Martinez, Onofre
Carolina Capozzi, Maria
Martinez, Lorena
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
[24] Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus
Da, Ben L.
Lourdusamy, Vennis
Kushner, Tatyana
Dieterich, Douglas
Saberi, Behnam
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (06) : 859 - 861
[25] Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection
Luisa Montes, Maria
Olveira, Antonio
Ahumada, Adriana
Aldamiz, Teresa
Garcia-Samaniego, Javier
Clemente, Ana
Berenguer, Juan
Gonzalez-Garcia, Juan
Martin-Carbonero, Luz
AIDS, 2017, 31 (09) : 1253 - 1260
[26] Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
Phil McEwan
Samantha Webster
Thomas Ward
Michael Brenner
Anupama Kalsekar
Yong Yuan
Cost Effectiveness and Resource Allocation, 15
[27] Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals
Hasson, Hamid
Merli, Marco
Messina, Emanuela
Bhoori, Sherrie
Salpietro, Stefania
Morsica, Giulia
Regalia, Enrico
Bagaglio, Sabrina
Lazzarin, Adriano
Uberti-Foppa, Caterina
Mazzaferro, Vincenzo
JOURNAL OF HEPATOLOGY, 2017, 67 (02) : 415 - 417
[28] Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)
David R. Walker
Marcos C. Pedrosa
Shivaji R. Manthena
Nikil Patel
Steven E. Marx
Advances in Therapy, 2015, 32 : 1117 - 1127
[29] Sofosbuvir-Velpatasvir With Ribavirin for 24 Weeks in Hepatitis C Virus Patients Previously Treated With a Direct-Acting Antiviral Regimen
Gane, Edward J.
Shiffman, Mitchell L.
Etzkorn, Kyle
Morelli, Giuseppe
Stedman, Catherine A. M.
Davis, Mitchell N.
Hinestrosa, Federico
Dvory-Sobol, Hadas
Huang, K. C.
Osinusi, Anu
McNally, John
Brainard, Diana M.
McHutchison, John G.
Thompson, Alex J.
Sulkowski, Mark S.
HEPATOLOGY, 2017, 66 (04) : 1083 - 1089
[30] Direct-Acting Antivirals in the Treatment of Hepatitis C Virus (HCV)/Human Immunodeficiency Virus (HIV) Co-infected Patients: Real-Life Experience From Nepal
Sudhamshu, K. C.
Karki, Niyanta
Sharma, Dilip
Khadka, Sandip
Tiwari, Pratap S.
CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (06)

← 1 2 3 4 5 →